RVTY
Revvity, Inc.
Diagnostics & Research · Healthcare · United States
165.78
close · 2026-10-29
value
77
cheaper than peers77
quality
46
stronger fundamentals46
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| price to book | 2.56× | 81 |
| EV to EBITDA | 17.44× | 79 |
| forward P/E | 28.12× | 58 |
| price to sales | 4.45× | 56 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 17.0% | 75 |
| debt to equity | 46.2% | 57 |
| return on equity | 3.2% | 53 |
| revenue growth | 1.3% | 15 |
4 of 4 measures available
Facts
| market cap | $18B |
| free cash flow | $599.4M |
| employees | 11,000 |
| first trade | 1973-02-21 |
| next earnings | 2026-11-03 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 2.07 | 2.20 | 5.55 | 4.58 |
| free cash flow | $509.4M | $541.7M | $9.9M | $594.2M |
| net income | $241.2M | $270.4M | $693.1M | $569.2M |
| revenue | $2.86B | $2.76B | $2.75B | $3.31B |
| unusual items | -$26.4M | $981,000 | -$71.9M | -$23.7M |